The Latest Cardiac and Vascular News
PhaseBio to be responsible for all development, manufacturing and commercialization MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has signed an agreement […]
SAN CARLOS, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Morph® DNA deflectable guide catheter used to guide the Helix™ Biotherapeutic Delivery System […]
Westport, CT, Jan. 14, 2020 (GLOBE NEWSWIRE) — Company allowed a fifth utility patent Claims address methods for removing voltage offset from biomedical signals Eleven additional patent applications covering PURE EPTM System are currently pending BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary […]
BOSTON, Jan. 13, 2020 /PRNewswire/ — Diagnosing CVD is the first step in patients’ road to recovery. It is imperative to detect the disease early in order to administer treatment while it is still treatable. In addition, preventing the disease altogether is becoming more important in healthcare. The main approaches for detecting CVD are […]
Lifesaving Solution Now Available Nationwide for Treatment of Acute Coronary Artery Perforations LAKE OSWEGO, Ore., April 10, 2019 /PRNewswire/ — BIOTRONIK today announced the United States (US) commercial launch of the PK Papyrus® covered coronary stent system for use in the emergency treatment of acute coronary perforations.1,2 More than 800,000 percutaneous coronary intervention procedures are performed annually […]
MARLBOROUGH, Mass., Jan. 14, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 percent on a reported basis, compared to the company’s guidance range of 13 to 15 percent; approximately 14.1 percent on […]
– New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population – If successful, the REPAIR MR study has potential to expand MitraClip’s current indication (patients at prohibitive risk for surgery) to also include patients at moderate […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance. Preliminary, unaudited revenue for fourth quarter 2019 is expected to be approximately […]
– 2019 Fiscal Year Revenues Expected to Increase 29% to $31.1 Million to $31.3 Million – – Full Year 2020 Revenue Guidance of $39.5 Million to $42.0 Million – CAESAREA, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive […]
BETonMACE Results Show 57% Hazard Reduction in Primary MACE for Patients on Apabetalone and New Oral Anti-Diabetic Treatments CALGARY, Alberta, Jan. 13, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce today additional highly significant findings and clear synergy when apabetalone is combined […]
